Accel Research Sites

DeLand, Florida 32720-0834

0 studies enrolling now · 13 studies all time

What they study most

Atrial Fibrillation, Drug-drug Interactions, Heart Failure, Hot Flashes, Influenza, Interstitial Cystitis/Bladder Pain Syndrome, Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention, OSA, Obese But Otherwise Healthy Participants, RSV, Respiratory Syncytial Virus Prevention, Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention

Studies at this site

• A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years — Completed
• A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation — Running, not enrolling
• A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats — Completed
• A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity — Running, not enrolling
• Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome — Completed
• A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults — Completed
• Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study) — Completed
• A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia — Completed
• A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older — Stopped early
• A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years — Completed
• A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old — Completed
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers — Completed
• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) — Completed